. Author manuscript; available in PMC: 2016 Apr 26.

Published in final edited form as: Biopharm Drug Dispos. 2016 Apr;37(3):123–141. doi: 10.1002/bdd.1996

Table 3.

Predictive performance of PBPK model

PK	n	< 2-fold^a	2–3 fold^a	AFE	AAFE	CCC
Total
C_max	22	22	0	0.867	1.46	0.933
AUC_0–t	22	21	1	0.951	1.31	0.976
t1/2	22	22	0	0.869	1.39	0.851
MRT	22	21	1	0.953	1.42	0.835
CL_h	22	21	1	1.08	1.36	0.919
Vss	22	20	2	1.03	1.38	0.963
Acid
C_max	7	7	0	0.771	1.49	0.896
AUC_0–t	7	7	0	1.17	1.29	0.964
t1/2	7	7	0	0.828	1.39	0.843
MRT	7	7	0	1.04	1.45	0.826
CL_h	7	7	0	0.865	1.34	0.866
Vss	7	7	0	0.895	1.22	−0.091
Neutral and Weak Base
C_max	8	8	0	1.07	1.36	0.787
AUC_0–t	8	8	0	0.871	1.37	0.899
t1/2	8	8	0	0.822	1.47	0.823
MRT	8	8	0	0.780	1.47	0.793
CL_h	8	8	0	1.22	1.36	0.805
Vss	8	7	1	0.950	1.55	0.549
Strong Base
C_max	7	7	0	0.769	1.54	0.790
AUC_0–t	7	6	1	0.857	1.27	0.920
t1/2	7	7	0	0.972	1.30	0.500
MRT	7	6	1	1.10	1.33	0.400
CL_h	7	6	1	1.19	1.37	0.770
Vss	7	6	1	1.31	1.38	0.940

a: number of drugs who have an AFE of less than 2 and 2–3, respectively.

n: number of drug; AFE: average fold-error; AAFE: absolute average fold-error; CCC: concordance correlation coefficient.